中文

← All funding rounds

Biossil

Drug discoveryToronto, CanadaPrivate

Uses OpenAI language models to find drug candidates that failed elsewhere and could work in a changed trial design or patient group, then licenses them and runs the new trials.

Disclosed total$153M
Rounds on record1
Latest round$153MVenture round · 2026-09-28
Last stated valuation$1Bstated by The Globe and Mail
Investors named8
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date$153M
Closed round

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-09-28Venture round
    Round

    $153M$1B · stated by The Globe and Mail

    For: expanding clinical development capacity and selectively acquiring more drug candidates

    Toward the clinic

    The Globe and Mail broke the round, where the CEO declined to comment; co-founder and CEO Anthony Mouchantaf then confirmed the details to BetaKit by email the same day. The Globe calls it an all-equity deal with a small portion paid to early employees, and says the fund provided the majority of the $153M. Both sources name the lead as the OpenAI Startup Fund. BetaKit says Biossil left stealth in April 2026 with $70M raised; The Globe and Mail says OpenAI co-led a $43M round a year earlier. Neither earlier round is recorded here.

    Lead · OpenAIFounders FundDuke University endowmentAbu Dhabi Investment CouncilExisting investor · Quiet CapitalExisting investor · Modern CapitalExisting investor · Golden Ventures ✓Existing investor · Panache Ventures

    Announced by the company · betakit.com ↗On the timeline →

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

On the investors' own sites

Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.

  • Golden VenturesLists Biossil in its portfolio, year invested 2023, with Anthony Mouchantaf and Alexander Mosa as its leaders.golden.ventures ↗

Its investors also backed

Other companies on this page whose rounds name the same investor.